Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$9.68
$0.61
$24.20
$820K1.4119,299 shs416,900 shs
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.78
-1.7%
$1.55
$1.00
$5.01
$16.54M0.4765,987 shs47,360 shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.03
$0.03
$0.25
$3.56
$826K2.34455,220 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00%0.00%0.00%0.00%0.00%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%-80.00%-82.96%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-1.66%-3.40%+1.71%+1.71%-34.56%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%-30.00%-6.67%+9.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.1781 of 5 stars
3.53.00.00.03.81.71.3
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00
N/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.00
Buy$12.20585.39% Upside
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACOR, SABS, ONVO, and SQZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $20.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$117.63M0.00N/A0.02($127.17) per share0.00
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$2.24M7.38N/AN/A$6.21 per share0.29
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.05N/AN/A$1.94 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$42.19M-$3.70N/AN/AN/A-1,450.14%-94.37%-67.26%8/14/2025 (Estimated)
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A

Latest ACOR, SABS, ONVO, and SQZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A
3/28/2025Q4 2024
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
3.07
0.33
0.26
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.09
3.69
3.69
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50

Institutional Ownership

CompanyInstitutional Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
12.71%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%

Insider Ownership

CompanyInsider Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
2.60%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
26.46%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
1111.24 million1.21 millionNo Data
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
1409.29 million6.79 millionNot Optionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
1,62029.49 million24.77 millionNot Optionable

Recent News About These Companies

Serica Energy shares drop as Triton suspended until mid-March
Serica Energy says 2025 outlook is ‘promising'
SQZ Biotechnologies Co Ordinary Shares
SQZ Biotechnologies Company (SQZB)
Sqz Bio (SQZB) Earnings Dates & Reports
VC funding update: who raised money in March?
SQZB SQZ Biotechnologies Company
SQZ Biotechnologies Co Ordinary Shares SQZB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acorda Therapeutics stock logo

Acorda Therapeutics NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$1.78 -0.03 (-1.66%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.97 +0.19 (+10.67%)
As of 05:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

SQZ Biotechnologies stock logo

SQZ Biotechnologies NYSE:SQZ

$0.03 0.00 (0.00%)
As of 05/23/2025

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.